1. Home
  2. MNPR vs MASS Comparison

MNPR vs MASS Comparison

Compare MNPR & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$70.28

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Logo 908 Devices Inc.

MASS

908 Devices Inc.

N/A

Current Price

$9.42

Market Cap

498.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MNPR
MASS
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
498.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MNPR
MASS
Price
$70.28
$9.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
6
Target Price
★ $130.17
$14.00
AVG Volume (30 Days)
127.0K
★ 336.2K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
54.99
★ 125.47
EPS
N/A
★ N/A
Revenue
N/A
★ $56,197,000.00
Revenue This Year
N/A
$23.13
Revenue Next Year
N/A
$18.66
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$50.07
$5.03
52 Week High
$124.82
$13.35

Technical Indicators

Market Signals
Indicator
MNPR
MASS
Relative Strength Index (RSI) 42.77 39.10
Support Level $66.88 $9.32
Resistance Level $75.33 $11.16
Average True Range (ATR) 4.74 0.84
MACD 0.73 -0.16
Stochastic Oscillator 51.81 19.52

Price Performance

Historical Comparison
MNPR
MASS

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

About MASS 908 Devices Inc.

908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.

Share on Social Networks: